<DOC>
	<DOCNO>NCT01103089</DOCNO>
	<brief_summary>The purpose study determine patient characteristic patient used Iressa period minimal 3 year .</brief_summary>
	<brief_title>Observations From Long Term Responders Gefitinib ( Iressa ) Expanded Access Program ( EAP )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Participation gefitinib Expanded Access Program Patient still use gefitinib September 2009</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>gefitinib</keyword>
	<keyword>observational</keyword>
</DOC>